Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from HBM Holdings Ltd. ( (HK:2142) ) is now available.
HBM Holdings Ltd. has entered a strategic collaboration with Otsuka Pharmaceutical Co., Ltd. to advance the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager for autoimmune diseases. This agreement grants Otsuka an exclusive license for global rights, excluding Greater China, and includes potential payments to HBM Holdings of up to $670 million, as well as tiered royalties on future sales. This partnership is expected to enhance HBM’s positioning in the T-cell engager market and may lead to further collaborations.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on the development of bispecific antibodies using its proprietary fully human HBICE bispecific technology and Harbour Mice platform. The company is involved in creating treatments for autoimmune and oncological diseases.
Average Trading Volume: 11,463,801
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.51B
Find detailed analytics on 2142 stock on TipRanks’ Stock Analysis page.